© 2005 by BMJ Publishing Group & British Cardiac Society
EDITORIAL
Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism?
National Heart & Lung Institute, Department of Clinical Cardiology, Imperial College School of Medicine, London, UK
Correspondence to:
Correspondence to:
Dr Stephan von Haehling
National Heart & Lung Institute, Department of Clinical Cardiology, Dovehouse Street, London SW3 6LY, UK; s.vonhaehling{at}imperial.ac.uk
Statins are being hailed as the new aspirin—but are they beneficial for patients with heart failure?
Abbreviations: CORONA, controlled rosuvastatin multinational trial in heart failure; CRP, C reactive protein; FDA, Food and Drug Administration; GISSI-HF, Gruppo Italiano per lo studio della sopravvivenza nell’insufficienza cardiaca; HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A; PUFA, polyunsaturated fatty acids
Keywords: heart failure; statins
Relevant Articles
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
Heart 2007 93: 1023.
Heart 2007 93: 902.
Heart 2007 93: 791.
Heart 2007 93: 655.
Heart 2007 93: 418.
Heart 2007 93: 286.
Heart 2007 93: 116.
Heart 2006 92: 1865.
Heart 2006 92: 1691.
Heart 2006 92: 1513.
Heart 2006 92: 1320.
Heart 2006 92: 1150.
Heart 2006 92: 974.
Heart 2006 92: 839.
Heart 2006 92: 696.
Heart 2006 92: 528.
Heart 2006 92: 400.
Heart 2005 91: 94.
This article has been cited by other articles:
-
Haynes, R., Bowman, L., Armitage, J.
(2009). Aspirin for primary prevention of vascular disease in people with diabetes. BMJ
339: b4596-b4596
[Full Text] -
Cooney, M. T., Dudina, A. L., Graham, I. M.
(2009). Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians.. J Am Coll Cardiol
54: 1209-1227
[Abstract] [Full Text] -
Poulter, N. R., Dobson, J. E., Sever, P. S., Dahlof, B., Wedel, H., Campbell, N. R.C., on behalf of the ASCOT Investigators,
(2009). Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial).. J Am Coll Cardiol
54: 1154-1161
[Abstract] [Full Text] -
Collins, G. S, Altman, D. G
(2009). An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study. BMJ
339: b2584-b2584
[Abstract] [Full Text] -
Ferrari, R.
(2008). Treatment with angiotensin-converting enzyme inhibitors: insight into perindopril cardiovascular protection. Eur Heart J Suppl
10: G13-G20
[Abstract] [Full Text] -
MacDonald, M.R., Hawkins, N.M., Balmain, S., Dalzell, J., McMurray, J.J.V., Petrie, M.C.
(2008). Transthoracic echocardiography: a survey of current practice in the UK. QJM
101: 345-349
[Abstract] [Full Text] -
Simon, C.
(2008). Prevention of stroke. InnovAiT
1: 305-313
[Full Text] -
Levine, A. P., Mikhailidis, D. P., Moross, T., Benson, K., Gor, M.
(2008). Achieving Vascular Risk Factor Targets: A Survey of a London General Practice. ANGIOLOGY
59: 36-46
[Abstract] -
Dunn, N.
(2008). Prevention of coronary heart disease in general practice. InnovAiT
1: 14-25
[Abstract] [Full Text] -
Hippisley-Cox, J, Coupland, C, Vinogradova, Y, Robson, J, Brindle, P
(2008). Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study. Heart
94: 34-39
[Abstract] [Full Text] -
Jialal, I., Miguelino, E., Griffen, S. C., Devaraj, S.
(2007). Concomitant Reduction of Low-Density Lipoprotein-Cholesterol and Biomarkers of Inflammation with Low-Dose Simvastatin Therapy in Patients with Type 1 Diabetes. J. Clin. Endocrinol. Metab.
92: 3136-3140
[Abstract] [Full Text] -
Hippisley-Cox, J., Coupland, C., Vinogradova, Y., Robson, J., May, M., Brindle, P.
(2007). Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ
335: 136-136
[Abstract] [Full Text] -
Staessen, J. A, O'Brien, E.
(2007). Will generic hypertension guidelines reduce the proliferation of directives?. Heart
93: 775-777
[Full Text] -
Barnett, A.H., Mackin, P., Chaudhry, I., Farooqi, A., Gadsby, R., Heald, A., Hill, J., Millar, H., Peveler, R., Rees, A., Singh, V., TayLor, D., Vora, J., Jones, P.B.
(2007). Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol
21: 357-373
[Abstract] -
Smellie, W S A, Forth, J, Smart, S R S, Galloway, M J, Irving, W, Bareford, D, Collinson, P O, Kerr, K G, Summerfield, G, Carey, P J, Minhas, R.
(2007). Best practice in primary care pathology: review 7. J. Clin. Pathol.
60: 458-465
[Abstract] [Full Text] -
Keigher, C., Avalos, G., Dunne, F.
(2007). Treating to target in type 2 diabetes. British Journal of Diabetes & Vascular Disease
7: 83-85
[Abstract] -
Jessani, S., Lip, G.Y.H., Barnett, A., Millane, T.
(2007). The JBS-2 guidelines on prevention of cardiovascular disease in clinical practice: an opportunity missed. QJM
100: 121-124
[Full Text] -
von Haehling, S., Doehner, W., Anker, S. D
(2007). Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res
73: 298-309
[Abstract] [Full Text] -
(2006). Early and intensive treatment: glycaemic control in type 2 diabetes. Diabetes and Vascular Disease Research
3: 145-146
-
Leite-Moreira, A F, Castro-Chaves, P
(2006). Heart failure: statins for all?. Heart
92: 1537-1538
[Full Text] -
Jessani, S., Tomson, J.
(2006). Measuring healthcare outcomes--a race to utopia?. JRSM
99: 486-486
[Full Text] -
Lloyd, K.
(2006). More on switching statins: Comments from Pfizer. BMJ
333: 655-655
[Full Text] -
Ramsey, S. D., Hobbs, F. D. R.
(2006). Chronic Obstructive Pulmonary Disease, Risk Factors, and Outcome Trials: Comparisons with Cardiovascular Disease. Proc Am Thorac Soc
3: 635-640
[Abstract] [Full Text] -
Izzat, L.
(2006). The MERCURY II trial: benefits of rosuvastatin. British Journal of Diabetes & Vascular Disease
6: 171-176
[Abstract] -
Mackenzie, D G.
(2006). Switching statins: NICE tool overestimates benefits of statins.. BMJ
332: 1512-1513
[Full Text] -
Reckless, J. P D
(2006). Diabetes and lipid lowering: where are we?. BMJ
332: 1103-1104
[Full Text] -
Mackenzie, D G., Forbes, J., Wild, S., Rutledge, P.
(2006). Preventing coronary heart disease: high baseline risk strategy and cost effectiveness of guidelines.. BMJ
332: 793-793
[Full Text] -
Leiter, L. A, Betteridge, D J., Chacra, A. R, Chait, A., Ferrannini, E., Haffner, S. M, Kadowaki, T., Tuomilehto, J., Zimmet, P., Newman, C. B, Hey-Hadavi, J., Walkinshaw, C., On Behalf Of The Audit Study Steering Committee,
(2006). AUDIT study. Evidence of global undertreatment of dyslipidaemia in patients with type 2 diabetes mellitus. British Journal of Diabetes & Vascular Disease
6: 31-40
[Abstract]
eLetters:
Read all eLetters
- Pleiotropism of statins includes adverse effects
- Peter Celec
- Online, 10 Jan 2005 [Full text]
- Full Text
- Full Text (PDF)
- Correction (v93,p1230)
- Submit a response
- Read responses to this article
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
- Citation Map
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
